Laval – October 12, 2026 -- A six-month pilot of a standardized cirrhosis clinical pathway raised follow-up office visit adherence by 9.0% in relative terms, to 51.1% from 46.9%, across 4,251 patients in five community gastroenterology practices, Bausch Health Companies Inc. and its GI unit Salix Pharmaceuticals announced.